JANE STREET GROUP, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 180 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.

Quarter-by-quarter ownership
JANE STREET GROUP, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$263,286
-61.1%
14,201
-76.8%
0.00%
Q2 2023$677,094
-42.1%
61,220
-29.7%
0.00%
Q1 2023$1,168,961
-71.2%
87,041
-70.0%
0.00%
-100.0%
Q3 2022$4,053,000
+33.3%
290,537
+55.5%
0.00%
Q1 2022$3,041,000
-40.3%
186,866
-40.3%
0.00%
-100.0%
Q4 2021$5,096,000
+13.5%
312,795
+3.5%
0.00%
+100.0%
Q3 2021$4,488,000
-27.7%
302,206
-2.8%
0.00%
-50.0%
Q2 2021$6,209,000
+91.7%
310,876
+121.5%
0.00%
+100.0%
Q1 2021$3,239,000
-48.7%
140,336
-45.1%
0.00%
-66.7%
Q4 2020$6,313,000
-16.0%
255,569
+41.0%
0.00%
-40.0%
Q3 2020$7,515,000
-45.7%
181,261
-37.2%
0.01%
-50.0%
Q2 2020$13,834,000
+317.3%
288,770
+448.5%
0.01%
+233.3%
Q1 2020$3,315,000
-76.7%
52,645
-54.2%
0.00%
-85.0%
Q4 2019$14,236,000
+1623.5%
114,886
+822.9%
0.02%
+1900.0%
Q3 2019$826,000
-21.4%
12,448
-5.7%
0.00%0.0%
Q2 2019$1,051,000
-84.7%
13,200
-78.5%
0.00%
-90.9%
Q1 2019$6,855,000
+185.3%
61,280
+157.0%
0.01%
+120.0%
Q4 2018$2,403,000
-42.6%
23,841
-28.1%
0.01%
-37.5%
Q3 2018$4,189,000
+67.4%
33,151
+11.1%
0.01%
+14.3%
Q2 2018$2,503,000
+5.6%
29,830
-22.6%
0.01%
+16.7%
Q1 2018$2,370,000
-17.0%
38,529
-21.1%
0.01%
-25.0%
Q4 2017$2,854,000
-23.4%
48,860
-23.9%
0.01%
-38.5%
Q3 2017$3,726,000
-0.6%
64,196
+107.2%
0.01%0.0%
Q2 2017$3,750,000
-65.8%
30,984
-69.3%
0.01%
-72.3%
Q4 2016$10,953,000
+292.0%
100,816
+493.8%
0.05%
+235.7%
Q3 2016$2,794,000
+3.9%
16,978
-9.9%
0.01%
+16.7%
Q2 2016$2,688,000
+33.3%
18,844
+20.0%
0.01%
+9.1%
Q1 2016$2,017,000
+204.7%
15,700
+254.2%
0.01%
+175.0%
Q4 2015$662,000
+110.8%
4,433
+241.0%
0.00%
+100.0%
Q2 2015$314,000
-97.0%
1,300
-96.5%
0.00%
-97.5%
Q1 2015$10,450,00037,0520.08%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders